Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CoDa Therapeutics begins Series B round with $19.2mm investment; later gets another $20mm

Executive Summary

CoDa Therapeutics Inc. (wound healing, inflammation, and tissue repair) raised $19.2mm from current investors Domain Associates, GBS Venture Partners, and BioPacificVentures in what the company says is the beginning of its Series B round. A second closing, with additional investors, is planned. CoDa will use some of the proceeds for a Phase II trial in the US, New Zealand, and Australia of its lead candidate Nexagon for chronic wounds.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies